Performance analysis of Drugs Made In America Acquisition (DMAAR)
Annual Return
Since Feb 25, 2025, DMAAR has had an average annual return of +8.79%, underperforming the benchmark SPY, which returned +19.33% annual.
| 2026 | 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.29% | +24.04% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.95% | -35.11% | -32.89% | +48.17% | +24.24% | -1.07% | +54.45% | -9.29% | |||||
| 2025 | -0.66% | -13.34% | -15.31% | +36.25% | -19.87% | +57.25% | -4.76% | +20.77% | -19.73% | +8.89% | -1.42% | +24.04% |
Drawdown analysis of Drugs Made In America Acquisition (DMAAR)
The maximum drawdown for the DMAAR was -81.09%, occurring on Mar 25, 2026. This drawdown has not yet recovered.
The current DMAAR drawdown is -26.13%.
Since Feb 25, 2025 DMAAR has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -81.09% | Sep 26, 2025 | 123 | Mar 25, 2026 | Ongoing | Ongoing | Ongoing |
| -33.71% | Feb 25, 2025 | 34 | Apr 14, 2025 | 66 | Jul 21, 2025 | 100 |
| -18.96% | Jul 22, 2025 | 15 | Aug 12, 2025 | 24 | Sep 16, 2025 | 39 |
| -8.18% | Sep 23, 2025 | 1 | Sep 24, 2025 | 2 | Sep 26, 2025 | 3 |
| -1.50% | Sep 17, 2025 | 3 | Sep 22, 2025 | 1 | Sep 23, 2025 | 4 |